Recommendation
Background
Several studies have examined the role of systemic antibiotic prophylaxis in prevention of catheter-related infection. A recent meta-analysis reviewed these studies in oncology patients [1]. Four studies used a prophylactic glycopeptide prior to catheter insertion. However, heterogeneity in these studies precludes making any conclusion regarding efficacy.
In a study examining the effect of ongoing oral prophylaxis with rifampin and novobiocin on catheter-related infection in cancer patients treated with interleukin-2 [2], a reduction in CRBSI was observed, even though 9 of 26 subjects (35%) discontinued the prophylactic antibiotics due to side effects or toxicity. In non-oncology patients, no benefit was associated with vancomycin administration prior to catheter insertion in 55 patients undergoing catheterization for parenteral nutrition [3]. Similarly, extending perioperative prophylactic antibiotics in cardiovascular surgery patients did not reduce central venous catheter colonization [4]. A recent Cochrane review of prophylactic antibiotics in neonates with umbilical venous catheters concluded that there is insufficient evidence from randomized trials to support or refute the use of prophylactic antibiotics [5].
Late onset neonatal sepsis is often due to coagulase negative staphylococci and is thought to frequently stem from infected central venous catheters. Five trials involved a total of 371 neonates comparing vancomycin by continuous infusion via parenteral nutrition or intermittent dosing, and placebo. The infants treated with vancomycin experienced less sepsis (RR .11; 95% CI .05-.24) and less sepsis due to coagulase negative staphylococci (RR .33; 95% CI .19–.59) [6]. However, mortality and length of stay were not significantly different between the two groups. There were insufficient data to evaluate the risk of selection for vancomycin resistant organisms.